National Illicit Drug Indicators Project (NIDIP)
NIDIP was established in the recognition that there was a greater need for the regular dissemination of trends in the epidemiology of drug-related harms in Australia.
NIDIP was established in the recognition that there was a greater need for the regular dissemination of trends in the epidemiology of drug-related harms in Australia.
There are growing efforts by pharmaceutical companies to develop opioid formulations that are less prone to misuse (particularly injection), dependence and diversion to illicit markets.
This project examines the cost-effectiveness of an integrated community development approach for reducing alcohol-related injury and violence among Aboriginal people in three rural locations in NSW.
There has been limited examination of how prisoners view and experience opioid substitution treatment (OST). This project aims to describe OST within NSW correctional centres and patient experiences of being in OST while in prison.
This project sought to clarify Australian drug and alcohol treatment funding; current and future service needs; the gap between met and unmet demand; and planning and funding processes for the future.
This project aimed to deliver:
This project aims To assess the psychometric properties of the Cannabis Withdrawal Scale (CWS) and to further assess the reliability and validity of the measure for use in clinical and research settings.
Young people with multiple and complex needs represent a minority of young people but they experience a disproportionately high burden of harm.
Platform 70 is a project of the National Partnership Agreement on Homelessness and commenced in 2011. The project has the following key objectives:
Cannabis is the most widely used illicit drug in Australia and its use is associated with an increased risk of involvement in motor vehicle accidents, work place accidents, mental health disorders, and respiratory and other health harms.
Attention Deficit Hyperactivity Disorder (ADHD) is a significant risk factor for the development of substance use disorders (SUD) in adolescence and adulthood, and ADHD complicates the course and treatment of SUD.